Benign Adrenocortical Tumors and the Detection of Nonadrenal Neoplasia
Table 5
Risk for benign neoplasia detected via other modalities.
Other benign neoplasm
Cases (adrenocortical tumor)
Controls (normal adrenal)
OR (95% CI)
AOR (95% CI)
n
400
400
Meningioma
11 (2.8%)
5 (1.3%)
2.23 (0.80, 7.14)
2.45 (0.61, 12.42)
Pituitary adenoma
4 (1.0%)
5 (1.3%)
0.80 (0.20, 3.03)
0.64 (0.07, 4.50)
Thyroid nodule
102 (25.5%)
68 (17.0%)
1.67 (1.19, 2.36)
1.77 (1.15, 2.74)
Thyroid nodule ≥ 10 mm
66 (16.5%)
35 (8.8%)
1.88 (0.98, 3.63)
1.72 (0.73, 4.13)
FNA benign thyroid
35 (8.8%)
17 (4.3%)
1.62 (0.82, 3.29)
2.12 (0.87, 5.50)
Hyperparathyroidism or parathyroid adenoma
14 (3.5%)
5 (1.3%)
2.87 (1.08, 8.93)
3.00 (1.00, 11.64)
Benign breast Mass
16 (6.0%)
10 (3.3%)
1.62 (0.73, 3.75)
3.25 (1.28, 8.78)
Breast cyst
24 (9.0%)
46 (15.0%)
0.49 (0.29, 0.81)
0.59 (0.31, 1.10)
Colon adenoma
164 (41.0%)
136 (34.0%)
1.34 (1.01, 1.79)
1.15 (0.80, 1.65)
Benign prostatic hyperplasia
27 (20.5%)
5 (5.3%)
5.71 (2.37, 17.00)
3.20 (1.14, 10.60)
Lipoma
53 (13.3%)
46 (11.5%)
1.17 (0.77, 1.79)
1.08 (0.63, 1.83)
Fibroid
86 (32.1%)
95 (31.0%)
0.88 (0.63, 1.22)
1.36 (0.89, 2.12)
Endometrial polyp
25 (9.3%)
35 (11.4%)
0.89 (0.40, 1.79)
0.78 (040, 1.49)
Cervical polyp
22 (8.2%)
31 (10.1%)
0.69 (0.39, 1.21)
0.92 (0.46, 1.82)
Ovarian cyst
54 (20.1%)
83 (27.1%)
0.60 (0.41, 0.86)
1.40 (0.85, 2.34)
Note. The unadjusted and adjusted odds ratio for patients with benign adrenocortical tumors (cases) compared with those with normal adrenal glands (controls) are presented along with 95% confidence intervals for each benign neoplasm. AOR: adjusted odds ratio; adjusted for age, sex, race, smoking status, BMI, duration imaging interval, hypertension, hyperlipidemia, composite diabetes (diabetes or prediabetes), coronary artery disease, and myocardial infarction.
